William Guyer, an insider at Corcept Therapeutics Inc (CORT), sold 1,235 shares of the company's stock at a price of $80.88 per share on December 1, 2025. The total transaction value amounted to approximately $100,000. Following this sale, Guyer retains 1,235 shares of Corcept.
Corcept Therapeutics, based in Redwood City, California, is a commercial-stage pharmaceutical company focused on developing treatments for severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating cortisol effects. The company has a market capitalization of $9.0 billion and reported a P/E ratio of 84.77 with an EPS of 0.89.
Insider transactions, such as this one, must be reported to the SEC, offering transparency into executives' views on their company's stock. While individual sales can provide insight, they should be considered alongside broader patterns of insider activity and other market factors. Investors are encouraged to examine trends in insider transactions over time rather than relying on isolated events.
Upcoming earnings for Corcept are scheduled for May 4, 2026, with an estimated EPS of -$0.07 and revenue expectations of $242.9 million. The following earnings report is due on July 29, 2026, with an estimated EPS of $0.12 and revenue of $250.0 million.